Drug Database
PA

paclitaxel

✓ Approved

Shanghai Yizhong Pharmaceutical · EGFR · 小分子

什么是 paclitaxel?

paclitaxel 是一种小分子,由Shanghai Yizhong Pharmaceutical研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Intravenous (IV)。

药物档案

公司Shanghai Yizhong Pharmaceutical
药物类别小分子, 单克隆抗体, 抗体
分子靶点EGFR, ERBB2, TUBB
给药途径Injectable (Others), Intravenous (IV)
状态Approved

作用机制

分子靶点

paclitaxel 作用于 3 个分子靶点:

EGFRepidermal growth factor receptor (ERBB1, NNCIS)
ERBB2erb-b2 receptor tyrosine kinase 2 (HER-2, c-ERB-2)
TUBBtubulin beta class I (TUBB1, CSCSC1)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

paclitaxel 针对 5 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Non-small cell lung cancer stage IV✓ Approved
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Non-small cell lung cancer metastatic✓ Approved
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Breast cancerPhase III
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Rectosigmoid cancerPhase I
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Pancreatic carcinomaPreclinical

相关研究文献

PubMedNature biomedical engineering2026-11-19

Designer mucin-responsive nanomedicine for enhanced solid tumour penetration and therapy.

Yu Na N, Gong Ningqiang N, Liu Juan J, Zhong Haiping H et al.

While nanomedicines hold great promise for solid tumour therapy, their penetration and access to tumour cells is limited by large glycosylated proteins called mucins that are enriched in the tumour microenvironment. Here we show that mucins induce the disassembly of self-assembled mPEG-polyester micellar nanoparticles into smaller unimers. Leveraging this finding, we designed a mucin-responsive, paclitaxel-conjugated nanomedicine (mrPNM) whose unimers are capable of escaping the mucin-binding barrier. Following intravenous injection, this designer mucin-responsive nanomedicine exhibited markedly deeper penetration than the mucin-nonresponsive nanomedicine and albumin, resulting in 3.9- and 1.5-fold increases in tumour cell delivery, respectively, in a pancreatic mouse tumour model. The mrPNMs also achieved superior tumour growth inhibition compared to both the mucin-nonresponsive nanomedicine and Abraxane, the FDA-approved nanoparticle albumin-bound paclitaxel, in three solid tumour models. The mucin-responsive nanomedicine platform could provide a general strategy for improving the treatment of solid tumours.

PMID 43052497
阅读全文 →
PubMedCancer medicine2026-11-19

Secondary Analysis of a Randomized Controlled Trial of Adjuvant Chemotherapy by PSA Response Following Radiotherapy.

Mihalcik Stephen Andrew SA, Regan Meredith M MM, Rosenthal Seth A SA, Bubley Glenn J GJ et al.

NRG Oncology RTOG 9902 was a randomized controlled trial of the addition of adjuvant chemotherapy (paclitaxel, oral etoposide, estramustine) to long-course androgen suppression and radiation for patients with high-risk prostate cancer. The trial closed early due to excess toxicity and found no benefit to chemotherapy at a median follow-up of 9.2 years. Immediate post-radiation PSA status was dichotomized at ≤ 0.2 ng/mL. Landmark analysis redefined starting times for disease-free survival (DFS), time to distant metastasis (TDM), and overall survival (OS) at 36 weeks post-radiation, when planned chemotherapy was complete. Exclusion criteria included non-receipt of radiation or assigned chemotherapy and pre-landmark DFS events or loss to follow-up. Hazard ratios (HR), 95% confidence intervals, and PSA-by-treatment interaction estimated by Cox or competing-risks regression. Of 333 patients analyzed: 190 without and 143 with chemotherapy. Chemotherapy was associated with improved DFS for patients with PSA > 0.2 (HR 0.59, 0.38-0.91), but not for those with PSA ≤ 0.2 (HR 0.94, 0.60-1.46), interaction p = 0.13. There was no association with chemotherapy relative to post-RT PSA for either TDM or OS. This analysis suggests that men with a post-radiation PSA > 0.2 may benefit from treatment intensification with adjuvant chemotherapy. Prospective trials adapting treatment by PSA response are indicated. Trial Number: NCT00004054 (ClinicalTrials.gov).

PMID 43053607
阅读全文 →
PubMedEuropean journal of pharmacology2026-11-18

Targeting oxidative stress with resveratrol mitigates structural degeneration and sensory hyperexcitability in chemotherapy-induced peripheral neuropathy.

Nan Guanghai G, Kang Nari N, Lin Lin L, Kim Kyeongmin K et al.

Chemotherapy-induced peripheral neuropathy (CIPN) is a dose-limiting adverse effect of antineoplastic treatments, characterized by persistent sensory dysfunction and chronic pain. With no disease-modifying therapies available, targeting its underlying oxidative stress, mitochondrial dysfunction and structural nerve damage is critical. Resveratrol, a polyphenolic compound with robust redox-regulatory properties, represents a compelling candidate to intercept these neurodegenerative processes. In this study, we investigated the therapeutic effects and neuroprotective mechanisms of resveratrol in a mouse model of paclitaxel-induced CIPN. Following paclitaxel administration, resveratrol was administered daily from post-injection day (PID) 7 to 13. Our multidisciplinary approach integrated behavioral assessment of hypersensitivity, redox analyses, molecular and electrophysiological evaluations in dorsal root ganglia (DRG), ultrastructural examination of sural nerves, and intraepidermal nerve fiber (IENF) quantification in plantar skin. Resveratrol significantly attenuated mechanical hypersensitivity. In the DRG, resveratrol reduced oxidative stress-associated DHE fluorescence, accompanied by restoration of AMPK-PGC-1α signaling and SOD2 expression. Resveratrol also exerted structural protective effects, as evidenced by the recovery of myelin protein levels, improved sural nerve ultrastructure, and attenuation of IENF degeneration. Furthermore, voltage-sensitive dye imaging (VSDI) demonstrated that resveratrol attenuated aberrant stimulus-evoked neuronal hyperexcitability in the DRG. Collectively, these findings demonstrate that resveratrol alleviates paclitaxel-induced CIPN by reducing oxidative stress, preserving peripheral nerve integrity, and attenuating aberrant sensory neuronal activities. By targeting multiple pathological features of CIPN, resveratrol may represent a promising therapeutic approach for alleviating established effects.

PMID 43051357
阅读全文 →
PubMedAmerican journal of cancer research2026-11-18

Carbon-ion beam irradiation combined with paclitaxel/nab-paclitaxel effectively induces cell death in pancreatic cancer cells.

Kang Hyun-Cheol HC, Kim Eun-Ho EH, Lee Won-Seok WS, Suzuki Masao M et al.

This study investigated the molecular mechanisms by which carbon-ion beam irradiation (IR), either alone or in combination with paclitaxel (PTX) or nab-PTX, induces cell death in pancreatic cancer (PC) cells in vitro. Human PC cell lines, PANC-1 and MiaPaCa-2, were treated with carbon-ion beam IR alone or combined with PTX/nab-PTX. Cell viability, caspase-3/7 activity, and the expression of apoptosis-, autophagy-, and angiogenesis-related genes and proteins were analyzed using quantitative real-time RT-PCR (RT-qPCR) and western blotting. Additionally, cell invasion assays were performed. We found that PANC-1 cells were more resistant to carbon-ion beam IR than MiaPaCa-2 cells; however, combination treatment with PTX/nab-PTX enhanced the cytotoxic effects of carbon-ion beam IR (1 Gy). Caspase-3/7 activity was increased by carbon-ion beam IR or PTX alone and was further elevated by the combination treatment. RT-qPCR analysis showed that combined carbon-ion beam IR and PTX decreased the expression of the pro-apoptotic gene Bax while increasing Bcl-2 expression in PANC-1 cells. Furthermore, carbon-ion beam IR, both alone and in combination with PTX, significantly increased the expression of the autophagy-related genes ATG7 and Beclin1 in PANC-1 cells. PTX/nab-PTX alone, or combined with carbon-ion beam IR, enhanced the expression of the apoptosis-associated proteins cleaved PARP and cleaved caspase-3 in both PC cell lines. Combination treatment with carbon-ion beam IR and PTX/nab-PTX effectively suppressed the expression of p-ERK and p-EGFR, but not p-AKT, in PANC-1 cells. In contrast, carbon-ion beam IR (1 Gy) alone, PTX/nab-PTX alone, or the combination treatment effectively inhibited p-ERK, p-EGFR, and p-AKT expression in MiaPaCa-2 cells. Additionally, carbon-ion beam IR combined with PTX significantly inhibited VEGF expression and cell invasion. In conclusion, carbon-ion beam IR in combination with PTX/nab-PTX effectively enhances PC cell death via apoptosis induction and reduces its invasive potential.

PMID 43047861
阅读全文 →
PubMedTherapeutic advances in medical oncology2026-11-18

Prognostic value of KELIM in Japanese patients with advanced high-grade serous ovarian carcinoma and its association with pathological absence of malignancy at interval debulking surgery: A retrospective study.

Kochi Yuki Y, Noguchi Daito D, Nagata Chie C, Ogasawara Midori M et al.

The CA-125 ELIMination rate constant K (KELIM) has been reported to predict prognosis and chemosensitivity in patients with high-grade serous ovarian carcinoma (HGSOC); however, Japanese data are limited. Dose-dense paclitaxel-carboplatin (ddTC) may benefit patients with high-risk features compared with conventional paclitaxel-carboplatin (cTC). Conversely, some patients receiving effective neoadjuvant chemotherapy (NAC) show no pathological malignancy at interval debulking surgery (IDS). To evaluate the prognostic value of KELIM in Japanese HGSOC, and explore its association with outcomes according to chemotherapy and pathological findings at IDS. Multicenter retrospective observational study. Patients with FIGO stage III/IV HGSOC treated between 2012 and 2021 were included. KELIM was calculated using at least three CA-125 values obtained during the first 100 days of first-line chemotherapy, including values from the first three cycles when available. First, we evaluated KELIM as a prognostic indicator using the conventional threshold of 1.0. Second, patients were stratified into "Good" (favorable KELIM plus complete cytoreduction) and "Poor" (unfavorable KELIM and/or residual tumor) cohorts, and survival outcomes were compared between ddTC and cTC within these cohorts. Third, among patients who underwent complete IDS, we evaluated the association between KELIM during NAC and absence of residual pathological malignancy. Among 309 patients, the median KELIM was 1.1. Using the conventional cut-off of 1.0, KELIM stratified progression-free survival (PFS) and overall survival (OS) with significant difference. The Good cohort showed better PFS/OS than the Poor cohort. Overall, ddTC was associated with longer PFS than cTC in multivariable analysis (adjusted HR 0.72, 95% CI 0.54-0.98). In the Poor cohort, ddTC improved OS (HR 0.65, 95% CI 0.43-0.99). Among 98 patients who underwent complete IDS, 24 had no residual malignancy and showed higher KELIM than those with residual disease (median 1.65 vs. 1.25, P < 0.001). KELIM predicted absence of malignancy with an AUC: 0.74, and ≥2.0 achieved ≥95% specificity. KELIM provided prognostic information in Japanese HGSOC patients. Moreover, higher KELIM may identify greater chemosensitivity and absence of residual malignancy at IDS; prospective validation is required before clinical application.

PMID 43048398
阅读全文 →
PubMedClinical medicine insights. Arthritis and musculoskeletal disorders2026-11-18

Unusual Presentation of Metastatic Bladder Cancer: A Case Report of Acrometastasis to the Hand and Review of the Literature.

Küçükşen Muhammed Furkan MF, Çolak Tahsin Sami TS, Göğer Yunus Emre YE, Esen Hacı Hasan HH et al.

Hand acrometastasis secondary to bladder cancer is a rare and exceptional entity. This report presents an unusual case involving the second metacarpal and carpal bones. A 56-year-old female with grade 3 (high-grade), pT4aN2 bladder squamous cell carcinoma was diagnosed following transurethral resection. She had a history of multiple bone and vaginal metastases. Seventeen months after diagnosis, she presented with pain, erythema, and swelling in the right hand. Imaging revealed osteolytic lesions in the second metacarpal and carpal bones, along with soft tissue invasion. Tru-cut biopsy confirmed metastatic disease of bladder origin. She received paclitaxel-carboplatin chemotherapy and palliative radiotherapy. A partial response was observed. The disease later progressed, and the patient died 7 months after the diagnosis of acrometastasis. Bladder cancer-related hand acrometastasis is rare. Its diagnosis depends on clinical suspicion and confirmatory imaging and pathology. Such cases highlight atypical spread and the need for multidisciplinary management.

PMID 43047862
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多paclitaxel